Max Mackenzie Quinn, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Azepines | 2 | 2018 | 334 | 0.270 |
Why?
|
| Triazoles | 2 | 2018 | 908 | 0.210 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2018 | 58 | 0.160 |
Why?
|
| Lung Neoplasms | 5 | 2018 | 13104 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2018 | 1692 | 0.140 |
Why?
|
| Drug Synergism | 2 | 2018 | 1794 | 0.140 |
Why?
|
| Acrylamides | 1 | 2018 | 255 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 323 | 0.130 |
Why?
|
| Urea | 1 | 2017 | 450 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 539 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2018 | 388 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2018 | 2949 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2017 | 826 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2018 | 850 | 0.110 |
Why?
|
| Aniline Compounds | 1 | 2018 | 986 | 0.110 |
Why?
|
| Thiophenes | 1 | 2017 | 589 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 5223 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 3554 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2018 | 5534 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 2133 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 2417 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 5524 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 5856 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 10183 | 0.060 |
Why?
|
| Proteins | 1 | 2018 | 6100 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 16690 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2018 | 3689 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11525 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 9240 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 6364 | 0.040 |
Why?
|
| Mutation | 3 | 2018 | 29786 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2018 | 10483 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 13693 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2018 | 677 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2018 | 844 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2018 | 494 | 0.030 |
Why?
|
| Mice | 5 | 2018 | 81201 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 640 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 2439 | 0.030 |
Why?
|
| Animals | 6 | 2018 | 168768 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1525 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 6313 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1941 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 18034 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 3505 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 21696 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 6489 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2725 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2018 | 2943 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 9735 | 0.020 |
Why?
|
| Cytokines | 1 | 2018 | 7323 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14561 | 0.010 |
Why?
|
| Apoptosis | 1 | 2017 | 9724 | 0.010 |
Why?
|
| Humans | 5 | 2018 | 744366 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 63107 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 35425 | 0.010 |
Why?
|
| Female | 2 | 2018 | 380193 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 213390 | 0.000 |
Why?
|
| Male | 1 | 2018 | 350115 | 0.000 |
Why?
|